Abstract

The present study examined the effects of administering selective 5-HT antagonists and agonists to rats tested in the elevated zero-maze (EZM) model of anxiety. The EZM paradigm has advantages over the elevated plus-maze (EPM) paradigm with respect to measuring anxiety, yet has been utilized less frequently. Three experiments were conducted each with a diazepam control (0.25, 0.5 and 0.75 mg/kg). In the first experiment, we administered the 5-HT2C antagonist RS 102221 (0.5, 1.0, and 2.0 mg/kg) and 5-HT2C agonist MK-212 (0.25, 0.5 and 0.75 mg/kg); in the second experiment, we administered the 5-HT3 antagonist Y-25130 (0.1, 1.0 and 3.0 mg/kg) and 5-HT3 agonist SR 57227A (0.1, 1.0 and 3.0 mg/kg), and in the third experiment, we administered the 5-HT4 antagonist RS 39604 (0.01, 0.1, 1.0 mg/kg) and 5-HT4 agonist RS 67333 (0.01, 0.1 and 0.5 mg/kg). The administration of 5-HT2/3/4 subtype antagonists all generated behavioral profiles indicative of anxiolytic-like effects in the EZM, which was apparent from examination of both traditional and ethological measures. While little effect was observed from 5-HT2 and 5-HT3 agonists, the 5-HT4 agonist RS 67333 was found to produce a paradoxical anxiolytic-like effect similar to that produced by the 5-HT4 antagonist RS 39604. We conclude by discussing the implications of these findings.

Highlights

  • Anxiolytic-like effects observed in rats exposed to the elevated zero-maze following treatment with 5-HT2/5-HT3/ 5-HT4 ligands

  • The present study examined the effects of administering selective 5-HT antagonists and agonists to rats tested in the elevated zero-maze (EZM) model of anxiety

  • While little effect was observed from 5-HT2 and 5-HT3 agonists, the 5-HT4 agonist RS 67333 was found to produce a paradoxical anxiolytic-like effect similar to that produced by the 5-HT4 antagonist RS 39604

Read more

Summary

Introduction

Anxiolytic-like effects observed in rats exposed to the elevated zero-maze following treatment with 5-HT2/5-HT3/ 5-HT4 ligands. I nterest in the role of the 5-HT receptors in the control of anxiety first arose when clinical trials revealed an anxiolytic-like effect of the non-selective 5-HT2 antagonist ritanserin in humans[1]. Since this time a number of preclinical trials have been carried out, the majority of which have employed non-selective ligands. Preliminary studies employing animal models of anxiety have, in general, demonstrated that a reduction in 5-HT neurotransmission plays a role in the effects of novel non-benzodiazepine anxiolytics[3], equivocal results for the effects of 5-HT subreceptor ligands have been reported, in studies using the elevated plus-maze paradigm (EPM)[4]. We tested the effects of the 5-HT2C antagonist RS-102221, the 5-HT2C agonist MK-212, the 5-HT3 antagonist Y-25130, the novel 5-HT3 agonist SR 57227A, the selective 5-HT4 antagonist RS 39604, and the high-affinity 5-HT4 partial agonist RS 67333

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call